drugset
drugset / Trial / NCT02512588

A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

NCT02512588 ↗

Phase 2 Completed 120 enrolled Balance Therapeutics
RandomizedCrossoverDouble-blindTreatment

Summary

This is a randomized, placebo-controlled, double-blind, multiple cohort, fixed-dose multiple crossover, dose-finding study of oral BTD-001 in adult patients with IH or Narcolepsy without cataplexy (Type 2).

Timeline

Start
2015-09
Primary completion
2018-02
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BTD-001 Unknown — Oral

Indications

idiopathic hypersomnia narcolepsy without cataplexy